Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

UPDATE: Bank Of America Downgrades TAL International After EPS Falls Short


In a report published Thursday, Bank of America analyst Ken Hoexter downgraded the rating on TAL International (NYSE: TAL) from Neutral to Underperform, and lowered the price target from $47.00 to $45.00.

In the report, Bank of America noted, “TAL reported normalized 2Q14 EPS of $0.95, down 11% year-over-year, shy of our $0.98 and consensus' $0.96 estimates. Leasing revenue was $145 million, $2.5 million below our target, although total revenue of $164 million was ahead of our $158 million estimate due to higher Equipment Trading Revenue. Utilization fell 20 bps year-over-year to 97.3%, but topped our 96.0% estimate. Operating income was $76 million, $2 million below our target due to the lower leasing revenues and higher than expected operating expenses.”

TAL International closed on Wednesday at $46.77.

Latest Ratings for TAL

Apr 2019DowngradesBuyHold
Mar 2019UpgradesEqual-WeightOverweight
Oct 2018MaintainsNeutralNeutral

View More Analyst Ratings for TAL
View the Latest Analyst Ratings

Posted-In: Bank of America Ken HoexterAnalyst Color Downgrades Analyst Ratings


Related Articles (TAL)

View Comments and Join the Discussion!

Latest Ratings

GRUBInitiates Coverage On
HOTHInitiates Coverage On
NDRAInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Bank Of America Upgrades Health Net On Good Upside Potential

UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue